CN1425025A

CN1425025A - Daptomycin analogs as antibacterial agents

Info

Publication number: CN1425025A
Application number: CN00818471A
Authority: CN
Inventors: J·赫尔; I·帕尔; M·莫利特克; J·斯德勒克; 喻向阳; J·斯尔沃曼; D·凯瑟; J·费恩; D·克瑞斯滕森; T·拉扎罗瓦; A·D·沃特森; 张艳
Original assignee: Cubist Pharmaceuticals LLC
Current assignee: Cubist Pharmaceuticals LLC
Priority date: 1999-12-15
Filing date: 2000-12-15
Publication date: 2003-06-18
Also published as: ZA200205106B; EP2295444A3; CA2393907A1; EP1884520A2; WO2001044272A3; US20020025924A1; JP2003517004A; MXPA02006029A; AU784755B2; WO2001044272A2; US7335725B2; EP1884520A3; JP4990456B2; BR0017026A; EP2298790A1; AU2268201A; US20050203006A1; KR20020063227A; EP1240181A2; IL150223A0

Abstract

The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.

Description

Lipopeptid as the novelty of antiseptic-germicide

Invention field

The present invention relates to novel lipopeptid compound.The invention still further relates to the pharmaceutical composition of these compounds and use the method for these compounds as antimicrobial compounds.The invention still further relates to the method and the intermediate that is used to prepare these compounds of these novel lipopeptid compounds of preparation.

Background of invention

Gram-positive infects increasing sharply of---comprising those that are caused by drug tolerant bacteria---sickness rate and causes the interest of people to the exploitation new antibiotic again.Shown that the compounds as useful antibiotic potentiality comprises the A-21978C lipopeptid, for example be described among United States Patent (USP) RE 32,333, RE 32,455, RE 32,311, the RE 32,310,4,482,487,4,537,717 and 5,912,226.Daptomycin is such member, and relevant clinically gram positive bacterium is had fungicidal activity in the strong external and body, and these bacteriums cause serious and life-threatening disease.These bacteriums comprise the resistance pathogenic agent, for example vancomycin tolerates property faecalis (VRE), X-1497 tolerance streptococcus aureus (MRSA), glycopeptide intermediate susceptibility streptococcus aureus (GISA), coagulase negative staphylococcus (CNS) and penicillin tolerance streptococcus pneumoniae (PRSP), they is seldom had can supply the alternate therapeutical agent.For example referring to Tally etc., 1999, Exp.Opin.Invest.Drugs 8:1223-1238.

Although placed hopes on, but the demand of new antibiotic is still being continued such as antiseptic-germicides such as daptomycins.A lot of pathogenic agent have been exposed to microbiotic commonly used repeatedly.This exposure has caused the selection of the different antibiotic bacterial strains of tolerance Broad spectrum antibiotics.The forfeiture that the microbiotic that is caused by resistance mechanism is renderd a service with effect makes microbiotic invalid, so can cause life-threatening infection, in fact can not treat.Along with the listing of new antibiotic, pathogenic agent can develop the tolerance of these new drugs or middle tolerance, in fact produces the demand to the new anti-bacterial agent trend, to resist these emerging bacterial strains.In addition, the compound of performance fungicidal activity will provide the advantage that is better than present bacteriostatic compound.Thereby novel synthetic antibacterial agents will expect and not only can be used for treatment " natural " pathogenic agent, and can be used for treating centre drug tolerance and drug tolerance pathogenic agent, because this pathogenic agent never is exposed to this novel antiseptic-germicide.In addition, new anti-bacterial agent can be to the dissimilar different effects of pathogenic agent performance.

Summary of the invention

The present invention is directed to this problem, novel lipopeptid compound be provided, they to broad spectrum of bacteria, comprise that drug tolerant bacteria has anti-microbial activity.And then, compound performance fungicidal activity of the present invention.

The present invention comprises the antimicrobial compounds of formula I on the one hand:

And salt,

Wherein R is:

Wherein X and X " be independently selected from C=O, C=S, C=NH, C=NR ^X, S=O or SO ₂

Wherein n is 0 or 1;

R wherein ^XBe selected from alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic radical, hydroxyl, alkoxyl group, carboxyl or carbalkoxy;

Wherein B is X " R ^Y, H, alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclic radical;

R wherein ^YBe selected from hydrogen, alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic radical or hydroxyl;

On the one hand, A is H, NH ₂, NHR ^A, NR ^AR ^B, heteroaryl, cycloalkyl or heterocyclic radical;

R wherein ^AAnd R ^BBe independently selected from alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic radical or carbalkoxy;

Wherein if n is 0, then A is selected from addition

With

Each R wherein ⁵⁰-R ⁵³Be independently selected from C ₁-C ₁₅Alkyl;

Its condition is that then A is not if B is that H and X are C=O

(a) by a substituting group NHC (O) R ^DThe pyridyl that replaces, or

(b) by a substituting group NHC (O) R ^DThe C that replaces ₅-C ₆Saturated cycloalkyl ring;

R wherein ^DBe C ₁-C ₁₇Unsubstituted alkyl or C ₂-C ₁₇Unsubstituted thiazolinyl;

If B is that H and n are 0, then A is not H;

In another aspect, A is an aryl;

Its condition is if B is that H and X are C=O, then the benzyl ring that do not replaced by following groups of A:

(a)-O-((C ₈-C ₁₅) unsubstituted alkyl), wherein said benzyl ring can further be replaced by a substituting group alternatively, and substituting group is selected from halo, nitro, (C ₁-C ₃) alkyl, hydroxyl, (C ₁-C ₃) alkoxyl group or (C ₁-C ₃) alkylthio; Or

(b)-NHC (O) R ^D, wherein this benzyl ring can further be replaced by 1-2 substituting group alternatively, and substituting group is independently selected from amino, nitro, (C ₁-C ₃) alkyl, hydroxyl, (C ₁-C ₃) alkoxyl group, halo, sulfydryl, (C ₁-C ₃) alkylthio, formamyl or (C ₁-C ₃) alkyl-carbamoyl; R wherein ^DBe defined as preamble;

In the third aspect of invention, A is alkyl, thiazolinyl, alkynyl, alkoxyl group or aryloxy;

Its condition is that then A is not if B is that H and X are C=O

(a)-(C ₁-C ₁₆Unsubstituted alkyl)-NH ₂

(b)-(C ₁-C ₁₀Unsubstituted alkyl)-NHC (O) R ^D, R wherein ^DBe defined as preamble;

(c)-C ₁-C ₁₈Alkyl is alternatively by hydroxyl, carboxyl or a C at the most ₁-C ₃Alkoxyl group or one to three halo substituting group replace;

(d)-C ₄-C ₁₈Unsubstituted thiazolinyl; Or

R wherein ⁵⁴Be selected from C ₁-C ₁₇-unsubstituted alkyl or C ₂-C ₁₇-unsubstituted thiazolinyl; R wherein ⁵⁵Be selected from hydroxyethyl, methylol, mercapto methyl, mercaptoethyl, methylmercaptoethyl, 2-thienyl, 3-indole methyl, optional substituted phenyl, substituting group is selected from halo, nitro, C ₁-C ₃-unsubstituted alkyl, hydroxyl, C ₁-C ₃-unsubstituted alkoxyl group, C ₁-C ₃-unsubstituted alkylthio, formamyl or C ₁-C ₃-unsubstituted alkyl formamyl; Or optional substituted benzyl, substituting group is selected from halo, nitro, C ₁-C ₃-unsubstituted alkyl, hydroxyl, C ₁-C ₃-unsubstituted alkoxyl group, C ₁-C ₃-unsubstituted alkylthio, formamyl or C ₁-C ₃-unsubstituted alkyl formamyl; Wherein t is 0 or 1, and wherein u is the integer from 1-3;

If B is that H and X are C=O, then X and A do not constitute the carboxylamine ester protecting group;

If B is that H and n are 0, then A is not C ₄-C ₁₄Unsubstituted alkyl;

In fourth aspect, B and A constitute 5-7 unit's heterocycle or heteroaryl ring together;

R wherein ¹Be:

Wherein X ' and X_ are independently selected from C=O, C=S, C-NH, C=NR ^X, S=O or SO ₂

Wherein m is 0 or 1;

R wherein ^{X '}Be selected from alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic radical, hydroxyl, alkoxyl group, carboxyl or carbalkoxy;

Wherein B ' is X_R ^{Y '}, H, alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclic radical;

R wherein ^{Y '}Be selected from hydrogen, alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic radical or hydroxyl;

Wherein A ' is H, NH ₂, NHR ^{A '}, NR ^{A '}R ^{B '}, alkyl, thiazolinyl, alkynyl, alkoxyl group, aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclic radical;

R wherein ^{A '}And R ^{B '}Be independently selected from alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic radical or carbalkoxy;

Wherein if m leads 0, then A ' is selected from addition With

Select as an alternative, wherein B ' and A ' constitute 5-7 unit's heterocycle or heteroaryl ring together;

R wherein ²Be

Wherein K and K ' constitute C together ₃-C ₇Cycloalkyl or heterocyclic ring or C ₅-C ₁₀Aryl or heteroaryl ring;

Wherein J is selected from hydrogen, amino, NHR ^J, NR ^JR ^K, alkyl, thiazolinyl, alkynyl, alkoxyl group, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclic radical, alkylamino, hydroxyl, sulfo-, alkylthio, alkenylthio group, sulfinyl, alkylsulfonyl, azido-, cyano group, halo,

With

Each R wherein ²⁴, R ²⁵And R ²⁶Be independently selected from the group of forming by alkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl, perhaps R ²⁴And R ²⁵Constitute 5-8 unit heterocyclic ring together;

R wherein ^JAnd R ^KBe independently selected from alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclic radical; Perhaps

Select as an alternative, wherein J and R ¹⁷Constitute 5-8 unit's heterocyclic radical or cycloalkyl ring together; Perhaps

Select as an alternative, wherein J and R ¹⁷And R ¹⁸Constitute 5-8 unit aryl, cycloalkyl, heterocyclic radical or heteroaryl ring together;

Each R wherein ¹⁷And R ¹⁸Be independently selected from by hydrogen, halo, hydroxyl, alkoxyl group, amino, sulfo-, sulfinyl, alkylsulfonyl and

The group of forming; Perhaps

R wherein ¹⁷And R ¹⁸Can constitute together by ketone acetal, thioketal,

With

The group of forming, wherein each R ²²And R ²³Be independently selected from the group of forming by hydrogen and alkyl.

In another embodiment, the present invention also provides pharmaceutical composition and the using method thereof that comprises formula I compound.

In further embodiment, the invention provides the method for preparation I compound and pharmaceutical composition thereof.

In further embodiment, the invention provides the compound that can be used as formula I compound intermediate.

In embodiment further, the invention provides the method for use formula I compounds for treating people bacterial infection.

Detailed description of the invention

Definition

Have their its ordinary meaning with molecular formula in this application, other has except the appointment.

Single hydrogen atom (H) represented in term " hydrogen ".

Term " acyl group " is defined as the carbonyl atomic group that is connected with alkyl, thiazolinyl, alkynyl, cycloalkyl, heterocyclic radical, aryl or heteroaryl, and example comprises ethanoyl and benzoyl without limitation.

Term " amino " expression contains two substituent nitrogen radicals, and substituting group is independently selected from the group of being made up of hydrogen, alkyl, cycloalkyl, carbalkoxy, heterocyclic radical, aryl, heteroaryl and alkylsulfonyl.The subclass of term amino is (1) term " a unsubstituted amino ", and it represents NH ₂Atomic group, (2) term " monobasic amino ", it is defined as containing a hydrogen and a substituent nitrogen radicals, substituting group is selected from alkyl, cycloalkyl, heterocyclic radical, aryl or heteroaryl, (3) term " dibasic amino ", it is defined as containing two substituent nitrogen radicals, and substituting group is independently selected from alkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl.Preferred monobasic amino atomic group is " rudimentary monobasic amino " atomic group, so substituting group is a low alkyl group.Preferred dibasic amino atomic group is " rudimentary dibasic amino " atomic group, so substituting group is a low alkyl group.

The oxygen atomic group that term " acyloxy " expression is adjacent with acyl group.

The nitrogen radicals that term " acyl amino " expression is adjacent with acyl group.

Term " carbalkoxy " is defined as and alkoxyl group or the adjacent carbonyl atomic group of aryloxy.

Term " formamido group " expression and amino adjacent carbonyl atomic group.

Term " halo " is defined as bromo, chloro, fluoro or iodo atomic group.

Term " sulfo-" expression contains the substituent group that is connected with bivalent sulfur atom, and substituting group is independently selected from hydrogen, alkyl, cycloalkyl, heterocyclic radical, aryl and heteroaryl, for example methylthio group and thiophenyl.

Term " alkyl " is defined as the saturated atomic group of straight or branched, has one to about 20 carbon atoms, and other has except the appointment.Preferred alkyl atomic group is " low alkyl group " atomic group, has one to about five carbon atoms.One or more hydrogen atoms can also be substituted base and replace, and substituting group is selected from acyl group, amino, acyl amino, acyloxy, carbalkoxy, carboxyl, formamido group, cyano group, halo, hydroxyl, nitro, sulfo-, alkyl, thiazolinyl, alkynyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl, alkoxyl group, aryloxy, sulfinyl, alkylsulfonyl, oxo, guanidine radicals, formyl radical and amino acid side chain.The example of alkyl comprises methyl, the tertiary butyl, sec.-propyl and methoxymethyl without limitation.The subclass of term alkyl is (1) " unsubstituted alkyl "; it is defined as not carrying substituent alkyl; (2) " alkyl of replacement "; it represents a kind of like this alkyl atomic group; wherein (a) one or more hydrogen atoms are substituted the base replacement; substituting group is selected from acyl group; acyloxy; carbalkoxy; carboxyl; formamido group; cyano group; nitro; sulfo-; alkyl; thiazolinyl; alkynyl; cycloalkyl; heterocyclic radical; aryl; heteroaryl; alkoxyl group; aryloxy; sulfinyl; alkylsulfonyl; N-alkylsulfonyl formamido group; N-acyl amino alkylsulfonyl; perhaps (b) two or more hydrogen atoms are substituted the base replacement separately, and substituting group is independently selected from hydroxyl; carboxyl; C ₁-C ₃Alkoxyl group, amino, acyl amino, oxo or guanidine radicals; (3) term " is selected the alkyl of replacement ", and it represents a kind of like this alkyl atomic group, and wherein (a) proton is substituted the base replacement, and substituting group is selected from hydroxyl, carboxyl, C ₁-C ₃Alkoxyl group, unsubstituted amino, acyl amino or acyl amino phenyl, perhaps (b) one to three proton is replaced by the halo substituting group.

Term " thiazolinyl " is defined as the straight or branched atomic group, has two to about 20 carbon atoms, is preferably three to about ten carbon atoms, and contains at least one carbon-to-carbon double bond.One or more hydrogen atoms can also be substituted base and replace, and substituting group is selected from acyl group, amino, acyl amino, acyloxy, carbalkoxy, carboxyl, formamido group, cyano group, halo, hydroxyl, nitro, sulfo-, alkyl, thiazolinyl, alkynyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl, alkoxyl group, aryloxy, sulfinyl, alkylsulfonyl, formyl radical, oxo and guanidine radicals.Two key parts of undersaturated hydrocarbon chain can be cis or transconfiguration.The example of thiazolinyl comprises vinyl or styryl without limitation.

Term " alkynyl " is defined as the straight or branched atomic group, has two to about ten carbon atoms, and contains at least one carbon-to-carbon, three key.One or more hydrogen atoms can also be substituted base and replace, and substituting group is selected from acyl group, amino, acyl amino, acyloxy, carbalkoxy, carboxyl, formamido group, cyano group, halo, hydroxyl, nitro, sulfo-, alkyl, thiazolinyl, alkynyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl, alkoxyl group, aryloxy, sulfinyl, alkylsulfonyl, formyl radical, oxo and guanidine radicals.The example of alkynyl comprises proyl without limitation.

Term " aryl " or " aryl rings " are illustrated in the aromatics atomic group in single or the fused iso system, have five to 14 ring memberses.In preferred embodiment, ring system has six to ten ring memberses.One or more hydrogen atoms can also be substituted base and replace, and substituting group is selected from acyl group, amino, acyl amino, acyloxy, azido-, alkylthio, carbalkoxy, carboxyl, formamido group, cyano group, halo, hydroxyl, nitro, sulfo-, alkyl, thiazolinyl, alkynyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl, alkoxyl group, aryloxy, sulfinyl, alkylsulfonyl and formyl radical.The example of aryl comprises phenyl, naphthyl, biphenyl, terphenyl without limitation.The subclass of term aryl is (1) term " phenyl ", and it represents following formula: compound: (2) term " phenyl of replacement "; it is defined as a kind of like this phenyl atomic group; wherein one or more protons are substituted base and replace; substituting group is selected from acyl group; amino; acyloxy; azido-; alkylthio; carbalkoxy; carboxyl; formamido group; cyano group; halo; hydroxyl; nitro; sulfo-; alkyl; thiazolinyl; alkynyl; cycloalkyl; heterocyclic radical; aryl; heteroaryl; alkoxyl group; aryloxy; sulfinyl; alkylsulfonyl; N-alkylsulfonyl formamido group and N-acyl amino alkylsulfonyl; (3) term " acyl amino phenyl "; it represents a kind of like this phenyl atomic group, and one of them hydrogen atom is replaced by acyl amino.Another one or a plurality of hydrogen atom can also be substituted base and replace, and substituting group is selected from acyl group, amino, acyl amino, acyloxy, azido-, alkylthio, carbalkoxy, carboxyl, formamido group, cyano group, halo, hydroxyl, nitro, sulfo-, alkyl, thiazolinyl, alkynyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl, alkoxyl group, aryloxy, sulfinyl, alkylsulfonyl, N-alkylsulfonyl formamido group and N-acyl amino alkylsulfonyl.

A kind of like this aromatics atomic group of " heteroaryl " or " heteroaryl ring " expression, it contains one to four heteroatoms or assorted group in single or condensed heterocycle ring system, be selected from O, N, S,

Or

And have five to 15 ring memberses.In preferred embodiment, the heteroaryl ring cording has six to ten ring memberses.One or more hydrogen atoms can also be substituted base and replace, and substituting group is selected from acyl group, amino, acyl amino, acyloxy, carbalkoxy, carboxyl, formamido group, cyano group, halo, hydroxyl, nitro, sulfo-, thiocarbonyl, alkyl, thiazolinyl, alkynyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl, alkoxyl group, aryloxy, sulfinyl, alkylsulfonyl and formyl radical.The example of heteroaryl comprises pyridyl, thiazolyl, thiadiazolyl group, isoquinolyl, pyrazolyl, oxazolyl, oxadiazole base, triazolyl and pyrryl without limitation.The subclass of term heteroaryl is (1) term " pyridyl ", and it represents following formula: compound:

(2) term " pyridyl of replacement "; it is defined as a kind of like this pyridyl atomic group; wherein one or more protons are substituted base and replace; substituting group is selected from acyl group; amino; acyloxy; carbalkoxy; carboxyl; formamido group; cyano group; halo; hydroxyl; nitro; sulfo-; alkyl; thiazolinyl; alkynyl; cycloalkyl; heterocyclic radical; aryl; heteroaryl; alkoxyl group; aryloxy; sulfinyl; alkylsulfonyl; N-alkylsulfonyl formamido group and N-acyl amino alkylsulfonyl; (3) term " acyl amino pyridyl "; it represents a kind of like this pyridyl atomic group; one of them hydrogen atom is replaced by acyl amino; another one or a plurality of hydrogen atom can also be substituted base and replace, and substituting group is selected from acyl group; amino; acyl amino; acyloxy; carbalkoxy; carboxyl; formamido group; cyano group; halo; hydroxyl; nitro; sulfo-; thiocarbonyl; alkyl; thiazolinyl; alkynyl; cycloalkyl; heterocyclic radical; aryl; heteroaryl; alkoxyl group; aryloxy; sulfinyl; alkylsulfonyl; N-alkylsulfonyl formamido group and N-acyl amino alkylsulfonyl.

Term " cycloalkyl " or " cycloalkyl ring " are defined as the saturated or undersaturated carbocyclic ring of part in single or the fused iso ring system, have three to 12 ring memberses.In preferred embodiment, cycloalkyl is the ring system with three to seven ring memberses.One or more hydrogen atoms can also be substituted base and replace, and substituting group is selected from acyl group, amino, acyl amino, acyloxy, carbalkoxy, carboxyl, formamido group, cyano group, halo, hydroxyl, nitro, sulfo-, alkyl, thiazolinyl, alkynyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl, alkoxyl group, aryloxy, sulfinyl, alkylsulfonyl and formyl radical.The example of cycloalkyl comprises cyclopropyl, cyclobutyl, cyclohexyl and suberyl without limitation.

Term " heterocyclic radical ", " heterocyclic " or " heterocycle " are defined as having the saturated or unsaturated ring of part in the single or annelated heterocycles ring system of three to 12 ring memberses, contain one to four heteroatoms or assorted group, be selected from O, N, NH,

(R wherein ^ZBe as R ^XDefined) S,

Or In preferred embodiment, heterocyclic radical is the ring system with three to seven ring memberses.One or more hydrogen atoms can also be substituted base and replace, and substituting group is selected from acyl group, amino, acyl amino, acyloxy, oxo, thiocarbonyl, imino-, carbalkoxy, carboxyl, formamido group, cyano group, halo, hydroxyl, nitro, sulfo-, alkyl, thiazolinyl, alkynyl, cycloalkyl, heterocyclic radical, aryl, heteroaryl, alkoxyl group, aryloxy, sulfinyl, alkylsulfonyl and formyl radical.The example of heterocyclic radical comprises morpholinyl, piperidyl and pyrrolidyl without limitation.

Term " alkoxyl group " expression is by the oxygen atomic group that contains of alkyl, cycloalkyl or heterocyclic radical replacement.Example comprises methoxyl group, tert.-butoxy, benzyloxy and cyclohexyloxy without limitation.

Term " aryloxy " expression is by the oxygen atomic group that contains of aryl or heteroaryl replacement.Example comprises phenoxy group without limitation.

Term " amino acid side chain " expression is from amino acid whose any side chain (R group) of natural existence or non-natural existence.

Term " sulfinyl " is defined as by an oxo substituting group and one the second tetravalence sulphur atom group that substituting group replaces, and second substituting group is selected from the group of being made up of alkyl, cycloalkyl, heterocyclic radical, aryl or heteroaryl.

Term " alkylsulfonyl " is defined as by two oxo substituting groups and one the 3rd sexavalence sulphur atom group that substituting group replaces, and the 3rd substituting group is selected from alkyl, cycloalkyl, heterocyclic radical, aryl or heteroaryl.

The amido protecting group that term " carbamate amido protecting group " is defined as generally acknowledging generates carbamate with amino bonded the time.The example of carbamate amido protecting group can be at " Protective Groups in Organic Synthesis ", Theodora W.Greene, and John Wiley and Sons, New York finds in 1981.The example of carbamate amido protecting group comprises carbobenzoxy-(Cbz), tertbutyloxycarbonyl, uncle's penta oxygen carbonyl, iso-borneol oxygen carbonyl, Buddha's warrior attendant carbalkoxy, benzyloxycarbonylchloride base, nitro carbobenzoxy-(Cbz) etc.

The salt of The compounds of this invention (being preferably formula I compound) comprises acid salt and base addition salt.In preferred embodiment, this salt is the pharmacy acceptable salt of formula I compound.The salt of the additive salt that is usually used in generating an alkali metal salt and free acid or free alkali contained in term " pharmacy acceptable salt ".The character of salt is not crucial, as long as it is pharmaceutically acceptable.The pharmaceutically-acceptable acid addition that is fit to of The compounds of this invention (being preferably formula I compound) can be from mineral acid or organic acid preparation.This class representative examples of mineral pigments comprises hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, nitric acid, carbonic acid, sulfuric acid and phosphoric acid without limitation.Suitable organic acid can be selected from the organic acid of aliphatic series, alicyclic, aromatics, aryl aliphatic series, heterocycle, carboxylic acid and sulfonic acid class, and the example comprises formic acid, acetate, propionic acid, succsinic acid, oxyacetic acid, gluconic acid, toxilic acid without limitation, pounces on acid, methylsulfonic acid, ethyl sulfonic acid, 2-ethylenehydrinsulfonic acid, pantothenic acid, Phenylsulfonic acid, toluenesulphonic acids, sulfanilic acid, methylsulfonic acid, cyclohexylsulfamic acid, stearic acid, alginic acid, beta-hydroxy-butanoic acid, propanedioic acid, gala acid and galacturonic acid.The pharmaceutically acceptable base addition salt that is fit to of The compounds of this invention (being preferably formula I compound) includes but not limited to from the metal-salt of aluminium, calcium, lithium, magnesium, potassium, sodium and zinc preparation with from N, the organic salt of N '-dibenzyl-ethylenediamin, chloroprocaine, choline, diethanolamine, quadrol, N-methylglucosamine, Methionin and PROCAINE HCL, PHARMA GRADE preparation.All these salt can be prepared from corresponding The compounds of this invention (being preferably formula I compound) according to conventional means, for example with The compounds of this invention (being preferably formula I compound) with suitable acid or alkaline purification.

The compounds of this invention (being preferably formula I compound) can have one or more asymmetric carbon atoms, thereby can have the form of optically active isomer and the form of racemize or non-racemic mixture thereof.The compounds of this invention (being preferably formula I compound) can be used as single isomer or as the mixture of stereochemistry heterogeneous and with in the present invention.Diastereomer, promptly can not can be separated by synergetic three-dimensional chemical isomer for example chromatogram, distillation, crystallization or distillation according to conventional means.Optically active isomer can obtain like this, and according to the ordinary method resolving racemic mixtures, for example the acid of usefulness optically active or alkaline purification are to generate diastereo-isomerism salt.The example of suitable acid comprises tartrate, diacetyl tartaric acid, dibenzoyl tartaric acid, dimethylbenzoyl tartrate and camphorsulfonic acid without limitation.The mixture of diastereomer can separate like this, first crystallization, the alkali of release optically active from these salt again.Can comprise the chiral chromatographic column that uses through optimized choice for the method for alternate separating optical isomers, with enantiomer separation farthest.Also have another kind of available method to relate to and make The compounds of this invention (being preferably formula I compound) and the activated form of optically pure acid or the diastereo-isomerism molecule of the synthetic covalency of optically pure isocyanate reaction.Institute's synthetic diastereomer can be separated according to conventional means, for example chromatogram, distillation, crystallization or distillation, and hydrolysis obtains the compound of enantiomer-pure then.Activity of optically active compounds of the present invention (being preferably formula I compound) can utilize the optically active raw material equally and obtain.These isomer can be the forms of free acid, free alkali, ester or salt.

Isolated compound is also contained in the present invention.Isolated compound refers to contain at least 10% compound in mixture, is preferably at least 20%, and more preferably at least 50%, most preferably be at least 80%.In preferred embodiment, compound, its pharmacy acceptable salt or comprise pharmaceutical composition performance detectable (being significant on the statistics) antimicrobial acivity of this compound, the conventional biological assay of testing is for example described herein.

Lipopeptid compound

The invention provides formula (I) compound:

And salt,

Wherein R is:

Wherein n is 0 or 1;

Wherein if n is 0, then A is selected from addition With

Its condition is that then A is not if B is that H and X are C=O

(a) by a substituting group NHC (O) R ^DThe pyridyl that replaces, or

If B is that H and n are 0, then A is not H;

In another aspect, A is an aryl;

Its condition is that then A is not if B is that H and X are C=O

(a)-(C ₁-C ₁₆Unsubstituted alkyl)-NH ₂

(d)-C ₄-C ₁₈Unsubstituted thiazolinyl;

Or

If B is that H and n are 0, then A is not C ₄-C ₁₄Unsubstituted alkyl;

R wherein ¹Be:

Wherein X ' and X_ are independently selected from C=O, C=S, C=NH, C=NR ^X, S=O or SO ₂

Wherein m is 0 or 1;

Wherein if m is 0, then A ' is selected from addition With

R wherein ²Be

Wherein J is selected from hydrogen, amino, NHR ^J, NR ^JR ^K, alkyl, thiazolinyl, alkynyl, alkoxyl group, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclic radical, alkylamino, hydroxyl, sulfo-, alkylthio, alkenylthio group, sulfinyl, alkylsulfonyl, azido-, cyano group, halo, With

The group of forming; Perhaps

R wherein ¹⁷And R ¹⁸Can constitute together by ketone acetal, thioketal, With

In preferred invention embodiment, R is selected from

Each R wherein ³, R ⁴, R ⁵And R ⁶Be independently selected from the group of forming by hydrogen, alkyl, aryl, heterocyclic radical and heteroaryl, wherein R ⁴⁴Be selected from the group of forming by alkyl, aryl, heterocyclic radical and heteroaryl.

In preferred invention embodiment, R is selected from

With

R wherein ^{4 '}Be selected from alkyl, the phenyl of replacement, heteroaryl, heterocyclic radical, optional substituted (C by alkyl, replacement ₈-C ₁₄)-straight chained alkyl and R wherein ⁷It is alkyl.

So preferred invention embodiment in, R is

With

X wherein ³Be chlorine or trifluoromethyl, wherein q is 0 or 1.

In preferred invention embodiment, R ¹Be selected from the group of forming by following formula:

With

R wherein ⁸Be selected from amino acid side chain, wherein said amino acid side chain can be naturally occurring or non-natural exists; Each R wherein ⁹, R ¹⁰And R ¹¹Be selected from hydrogen, alkyl, aryl, heterocyclic radical and heteroaryl; R wherein ¹²Be selected from the group of forming by heterocyclic radical, heteroaryl, aryl and alkyl; R wherein ¹³Be selected from (C ₁-C ₃)-alkyl and aryl.

In preferred invention embodiment, R ¹Be selected from the group of forming by following formula: With

R wherein ⁸Be selected from tryptophane side chain and lysine side-chain; Each R wherein ¹⁰And R ¹¹Be independently selected from hydrogen and alkyl; R wherein ¹²Be selected from imidazolyl, N-methylimidazolyl, indyl, quinolyl, benzyloxy benzyl and benzyl piepridine base benzyl; X wherein ⁴Be selected from fluorine and trifluoromethyl.

At preferred R ²In the embodiment, J be selected from by hydrogen, amino, azido-and

The group of forming; R wherein ¹⁷And R ¹⁸Primordial group together, be selected from by ketone acetal, With

The group of forming is selected as an alternative, if R ¹⁸Be hydrogen, R then ¹⁷It is hydroxyl; Select as an alternative, wherein J and R ¹⁷Constitute heterocyclic ring together.

In preferred invention embodiment, R ²Be selected from

With

R wherein ¹⁷And R ¹⁸Constitute together and be selected from With Group, R wherein ²²Be selected from the group of forming by H and alkyl; R wherein ¹⁹Be selected from by hydrogen, amino, azido-and

The group of forming.

So preferred invention embodiment in, R ²Be

Table I provides the formula I compound of demonstration: Table I

Preferred formula I compound is compound 2, compound 3, compound 18, compound 48, compound 89, compound 116, compound 118 and compound 120.

Other preferred compounds comprise formula (I ') compound:

R wherein ¹⁰⁰, R ¹⁰¹And R ¹⁰²It is defined: Table II as Table II

According to preferred embodiment, the invention provides one or more crystal formations of formula (I) compound and salt thereof.

The lipopeptid intermediate

The present invention also provides as the preparation intermediate of formula I compound and useful especially compound.These compounds also can have antibacterial properties, as mentioned above.The present invention provides formula II compound on the one hand:

R wherein ¹⁴Be selected from the group of forming by following formula: With

R wherein ⁵⁶It is optional substituted straight chain C ₈-C ₁₄Alkyl, wherein q ' is 0-3.

Intermediate in synthetic all is useful to compound 1,2,18,48,116,118 and 120 as antimicrobial compounds and The compounds of this invention.

Compound 72,73 and 74 and Table III in formula (II) compound be other preferred compounds, the intermediate in synthetic all is useful as antimicrobial compounds and The compounds of this invention for they.

Table III

Table IV provides another group formula (II) compound, and the intermediate during they synthesize as The compounds of this invention is useful.Table IV

Compound #	????R ¹⁴
Compound #	????R ¹⁴	????150	????(CH ₂) ₇CH ₃
????151	????(CH ₂) ₈CH ₃	????150	????(CH ₂) ₇CH ₃
????151	????(CH ₂) ₈CH ₃	????152	????(CH ₂) ₉CH ₃
????153	????(CH ₂) ₁₀CH ₃	????152	????(CH ₂) ₉CH ₃
????153	????(CH ₂) ₁₀CH ₃	????154	????(CH ₂) ₁₁CH ₃
????155	????(CH ₂) ₁₂CH ₃	????154	????(CH ₂) ₁₁CH ₃

The present invention provides the formula III compound on the other hand, and they are useful formula I compound intermediates as/or antimicrobial compounds:

R wherein ¹⁵Be selected from hydrogen and carboxylamine ester protecting group, be preferably tertbutyloxycarbonyl; R wherein ¹⁶Be selected from the group of forming by following formula:

With

R wherein ⁵⁷Be halo or haloalkyl, be preferably fluoro or trifluoromethyl; R wherein ²⁰Be amino acid side chain, be preferably Methionin or tryptophane side chain.

Lipopeptid compound pharmaceutical composition and using method thereof

Another object of the present invention provides lipopeptid compound or its salt and comprises lipopeptid compound or the pharmaceutical composition of its salt or preparation.

Lipopeptid compound or its pharmacy acceptable salt can be mixed with the formulation of oral, intravenously, intramuscular, subcutaneous or administered parenterally, be used for the treatment of or preventing disease, particularly infectation of bacteria.About oral or administered parenterally, lipopeptid compound of the present invention and conventional pharmaceutical carrier and mixed with excipients can be used with forms such as tablet, capsule, elixir, suspension, syrup, paper wafers.The composition that comprises The compounds of this invention will contain 0.1 active compound to about 99 weight % of having an appointment, and be more generally about 10 to about 30%.

Pharmaceutical preparation disclosed herein prepares according to standard program, and according to selected dosed administration, to reduce, to prevent or to eliminate and infect (for example referring to Remington ' sPharmaceutical Sciences, Mack Publishing Company, Easton, PA and Goodman and Gilman ' s The Pharmaceutical Basis of Therapeutics, Pergamon Press, New York, NY, its content is incorporated herein by reference, about the general remark of the medication of various biocides in people's therapy).Can utilize the release system (for example capsule) of sustained release or the composition that sustained-release delivery systems (the erodible matrix of biological example) discharges the present invention's (being preferably formula I).Be suitable for the drug delivery system that the exemplary delay of the present invention's's (being preferably formula I) composition administration discharges and be described in U.S. Patent No. 4,452,775 (awarding to Kent), 5,239,660 (awarding to Leonard), 3,854,480 (awarding to Zaffaroni).

Pharmaceutically acceptable composition of the present invention comprise one or more The compounds of this invention (being preferably formula I compound) and one or more nontoxic, pharmaceutically acceptable carrier and/or thinner and/or auxiliary agent and/or vehicle, this paper is referred to as " carrier " material, also has other activeconstituentss if necessary.Composition can contain common carrier and vehicle, for example W-Gum or gelatin, lactose, sucrose, Microcrystalline Cellulose, kaolin, mannitol, Lin Suanergai, sodium-chlor and alginic acid.Composition can contain croscarmellose sodium, Microcrystalline Cellulose, W-Gum, primojel and alginic acid.

The tablet binder that can comprise is gum arabic, methylcellulose gum, Xylo-Mucine, polyvinylpyrrolidone (polyvidone), Vltra tears, sucrose, starch and ethyl cellulose.

Operable lubricant comprises Magnesium Stearate or other metallic stearates, stearic acid, silicone fluid, talcum, wax, oil and colloid silica.

Can also use correctives, for example peppermint, wintergreen oil, cherry seasonings etc.Also may need to add tinting material, make formulation more attractive in appearance in appearance or help to discern product.

About orally using, solid preparation is useful especially, for example tablet and capsule.Can also design and continue to discharge or enteric coated preparation.Use about paediatrics and geriatrics, suspension, syrup and chewable tablet are especially to be fit to.About oral administration, pharmaceutical composition for example is the form of tablet, capsule, suspension or liquid.Preferably pharmaceutical composition is made the form of dosage device, wherein contained effective amount of actives on the therapeutics.The example of this class dosage device is tablet and capsule.For therapeutic purpose, tablet and capsule can also contain conventional carrier, for example tackiness agent, for example gum arabic, gelatin, polyvinylpyrrolidone, Sorbitol Powder or tragacanth gum except activeconstituents; Weighting agent, for example calcium phosphate, glycine, lactose, W-Gum, Sorbitol Powder or sucrose; Lubricant, for example Magnesium Stearate, polyoxyethylene glycol, silicon-dioxide or talcum; Disintegrating agent, for example yam starch; Correctives or tinting material, or acceptable wetting agent.Oral liquid generally is the form of water-based or oily solution, suspension, emulsion, syrup or elixir, can contain conventional additive, for example suspension agent, emulsifying agent, non-water reagent, sanitas, tinting material and correctives.The example of liquid preparation additive comprises gum arabic, Prunus amygdalus oil, ethanol, fractionated coconut oil, gelatin, glucose syrup, glycerine, hydrogenation edible fat, Yelkin TTS, methylcellulose gum, methyl p-hydroxybenzoate or propyl ester, propylene glycol, Sorbitol Powder or Sorbic Acid.

Use about intravenously (IV), lipopeptid compound according to the present invention can be dissolved or suspended in the intravenous fluid commonly used arbitrarily, by the infusion administration.Intravenous fluid comprises physiological saline or Ringer's solution without limitation.Intravenous administration can utilize syringe, micro pump or intravenous line to be realized without limitation.

Parenteral formulations can be the form of water-based or non-aqueous isoosmotic aseptic injectable solution or suspension.These solution or suspension can wherein contain one or more and be used for the carrier that oral Preparation is mentioned from aseptic powder or granules preparation.Compound can be dissolved in polyoxyethylene glycol, propylene glycol, ethanol, Semen Maydis oil, phenylcarbinol, sodium-chlor and/or various damping fluid.

About the intramuscular preparation, the soluble salt form that is fit to of lipopeptid compound or this compound, the sterile preparation of for example hydrochloride are dissolved and administration, for example water for injection (WFI), physiological saline or 5% glucose in pharmaceutical diluents.Can prepare the insoluble form that is fit to of this compound, as the suspension administration in aqueous matrix or pharmaceutically acceptable oleaginous base, oleaginous base is the ester of longer chain fatty acid for example, for example ethyl oleate.

Potion intravenously, intramuscular or the parenteral administration of lipopeptid compound can be used as the administration of medicine group or by slow infusion administration.The administration in of medicine group less than 30 minutes.In preferred embodiment, the administration in of medicine group less than 15 or 10 minutes.In preferred embodiment, the administration in of medicine group less than 5 minutes.So preferred embodiment in, medicine group one minute or following in administration.Infusion is to carry out according to 30 minutes or above speed.In preferred embodiment, infusion carried out one hour or more than.In another embodiment, infusion is constant speed basically.

Use about the part, The compounds of this invention can also be made the formulation that is suitable for skin or nose and throat mucous membrane, can take the form of creme, ointment, liquid spray or inhalation, lozenge or throat paint.This class topical formulations further can comprise such as dimethyl sulfoxide (DMSO) compounds such as (DMSO), to promote the surface seepage of activeconstituents.

About eyes or ear medication, The compounds of this invention can be liquid or semi-liquid form, is mixed with ointment, creme, lotion, paint or pulvis in hydrophobicity or hydrophilic matrix.

About rectal administration, The compounds of this invention can wherein be mixed with conventional carrier, for example theobroma oil, wax or other glyceryl ester with the form administration of suppository.

Select as an alternative, The compounds of this invention can be Powdered, is regenerating in suitable pharmaceutically acceptable carrier in the release.In another embodiment, the unit dosage of compound can be this compound or the solution of the salt that is preferably it in the thinner that is fit to, and is contained in the ampoule or sterile syringe aseptic, sealing.The concentration of compound in unitary dose for example can not wait from about 1% to about 50%, and this is determined according to used compound and solubleness thereof and required dosage by the doctor.If composition contains dosage device, each dosage device preferably contains the 1-500mg active material so.About adult treatment, preferably from 5mg to 10g every day, this depends on the approach and the frequency of administration to the dosage that is adopted.

The present invention provides the method that suppresses microorganism, is preferably bacterial growth on the other hand, comprise make described biology with The compounds of this invention, be preferably formula I compound and contact, the condition of contact is that this compound of permission enters described biology and described microorganism.This class condition is well known by persons skilled in the art, exemplifies in an embodiment.This method relates to the The compounds of this invention that makes significant quantity on microorganism cells and the therapeutics, is preferably in the formula I chemical combination object or external the contact.

According to this respect invention, novel composition disclosed herein is placed pharmaceutically acceptable carrier, discharge to the curee (preferably being the people) according to the known drug method for releasing.In general, the inventive method that is used for the release present composition in the body is utilized art-recognized drug release scheme, and material alterations is only arranged on program, with the medicine in the art-recognized scheme of The compounds of this invention (being preferably formula I compound) replacement.Equally; use compositions-treated cells in culture required for protection for example to utilize the art-recognized scheme of handling cell culture with antiseptic-germicide with the method for eliminating or reduce the bacterial contamination level of cell culture; material alterations is only arranged, with the medicine in the art-recognized scheme of The compounds of this invention (being preferably formula I compound) replacement on program.

In one embodiment, the invention provides with significant quantity on the therapeutics according to the lipopeptid compound of formula I treatment curee's infection, those the method that especially causes by gram-positive microorganism.The demonstration programme that is used for delivery of antimicrobials is described in the U.S. Patent No. 5,041,567 and PCT patent application No.EP 94/02552 (publication number WO 95/05384) of awarding to Rogers, and the complete content of these documents all is incorporated herein by reference.The outbreak of wording used herein " significant quantity on the therapeutics " expression The compounds of this invention prevention infectation of bacteria, alleviate its symptom or stop the amount of its progress.Term " treatment " is defined as the curee is given the The compounds of this invention (being preferably formula I compound) of significant quantity on the therapeutics, both generations of preventing infection, and also control or elimination are infected.Term described herein " curee " is defined as Mammals, plant or cell culture.In preferred embodiment, the curee is people or other animal patient that needs the lipopeptid compound treatment.

This method comprises the The compounds of this invention of the curee being given effective dose.Effectively dosage generally about 0.1 and about 100mg/kg formula I lipopeptid compound or its pharmacy acceptable salt between.Preferred dosage from about 0.1 to about 50mg/kg formula I lipopeptid compound or its pharmacy acceptable salt.More preferred dose from about 1 to about 25mg/kg formula I lipopeptid compound or its pharmacy acceptable salt.The effective dosage of pair cell culture is usually between 0.1 and 1000 μ g/mL, more preferably between 0.1 and 200 μ g/mL.

Formula I compound can be used as single daily dose administration or every day dosed administration several times.The treatment system may need long term administration, for example some day or two to around.The dosage of each administration or total dosage will depend on such factor, and for example character of Gan Raning and seriousness, patient's age and general health situation, patient are to one or more related microorganisms in the tolerance of compound and the infection.Another member's daptomycin of lipopeptid compound class is disclosed in the U.S. Patent application No.09/406 that submitted on September 24th, 1999 to the method for patient's administration, in 568, this application requires the U.S. Provisional Application No.60/101 of submission on September 25th, 1998, the U.S. Provisional Application No.60/125 that on March 24th, 828 and 1999 submitted to, 750 right of priority.

Can also be with lipopeptid compound according to the present invention administration in patient's diet or animal-feed.If as a part of administration of total diet picked-up, the amount of the compound that is adopted can preferably be no more than 0.5 weight % less than 1% of diet weight so.Animal-feed can be normal food, can be to wherein or add compound in premixture.

Method of the present invention comprises formula I lipopeptid compound or its pharmaceutical composition by the amount that effectively reduces or eliminates infectation of bacteria their curee's administration of needs.The administering mode of compound can be oral, parenteral, suction, part, rectum, nose, cheek, vagina or the Drug Storage of implantation, outer pump or conduit.Compound can be made a form usefulness or atomizing.Of the present inventionization thing can be used as aerosol drug delivery, is used for the treatment of pneumonia or other lung classes and infects.Preferred aerosol release vehicle is anhydrous or Foradil Aerolizer formoterol fumarate.Can also or be administered into abscess, chamber or intraarticular with formula I lipopeptid compound or its pharmaceutical composition direct injection.That administered parenterally comprises is subcutaneous, in the intravenously, intramuscular, intraarticular, synovial membrane, the pond, in the sheath, in the liver, in the damage and intracranial injection or infusion.In preferred embodiment, lipopeptid compound is intravenously, subcutaneous or oral administration.In will preferred implementation according to the lipopeptid compound pair cell culture administration of formula I, can be with compound administration in nutritional medium.

Method of the present invention can be used for the treatment of the curee of infectation of bacteria, and wherein this infection is by the bacterium of any type, particularly gram positive bacterium caused or worsened.In one embodiment, with lipopeptid compound or its pharmaceutical composition according to method of the present invention to patient's administration.In preferred embodiment, this infectation of bacteria is to be caused or worsened by gram positive bacterium.These gram positive bacteriums include but not limited to that X-1497 susceptibility and X-1497 tolerance staphylococcus (comprise streptococcus aureus, staphylococcus epidermidis, staphylococcus haemolyticus, staphylococcus hominis, Staphylococcus saprophyticus and Thrombin coagulase-negative staphylococcus), glycopeptide mediation susceptibility streptococcus aureus (GISA), penicillin susceptibility and penicillin tolerance suis (comprise streptococcus pneumoniae, streptococcus pyogenes, streptococcus agalactiae, streptococcus avium, streptococcus bovis, streptococcus acidi lactici, Streptococcus sanguis and C family suis, G family suis and viridans streptococci), faecalis (comprising vancomycin susceptibility and vancomycin tolerance property bacterial strain, for example enterococcus faecalis and faecium), difficult clostridium, fusiformis clostridium, clostridium innocuum, bacillus aerogenes capsulatus, racemosus clostridium, hemophilus influenzae, bacterium monocytogenes, C. jeikeium, bifidus bacillus, the aerogenesis Eubacterium, eubacterium lentum, Lactobacterium acidophilum, lactobacterium casei, lactobacillus plantarum, galactococcus, leukonid, micrococcus, peptostreptococcus anaerobius, peptostreptococcus asaccharolyticus, peptostreptococcus magnus, little peptostreptococcus, peptostreptococcus prevotii, peptostreptococcus productus, propionibacterium acnes, actinomycetes, mora gram Salmonella (comprising mucositis mora gram Salmonella) and escherich's bacillus (comprising intestinal bacteria).

In preferred embodiment, formula I lipopeptid compound in experiment in vitro to typical case " tolerance " bacterial strain anti-microbial activity be equivalent to typical case " susceptibility " bacterial strain anti-microbial activity.In another preferred embodiment, lipopeptid compound according to the present invention is generally equal to minimum inhibition concentration (MIC) value of susceptibility bacterial strain or is lower than vancomycin.Thereby in preferred embodiment, with lipopeptid compound of the present invention or its pharmaceutical composition according to method of the present invention to other compounds of performance tolerance, comprise patient's administration of the infectation of bacteria of vancomycin or daptomycin.In addition, different with glycopeptide antibiotic, lipopeptid compound to the biological performance of Gram-positive fast, the concentration dependent fungicidal activity.Thereby in preferred embodiment, will carry out patient's administration of antibiotic therapy fast to needs according to method of the present invention according to lipopeptid compound of the present invention or its pharmaceutical composition.

Method of the present invention can be used for any infectation of bacteria of any organ or tissue of body.In preferred embodiment, this infectation of bacteria is caused by gram positive bacterium.These organ or tissues comprise skeletal muscle, skin, blood flow, kidney, the heart, lung and bone without limitation.Method of the present invention can be used for treating without limitation skin and soft tissue infection, microbemia and urinary tract infection.Method of the present invention can be used for the treatment of the acquired respiratory infection of the public, comprises otitis media, sinusitis, chronic bronchitis and pneumonia without limitation, comprises the pneumonia that is caused by resistance streptococcus pneumoniae or hemophilus influenzae.Method of the present invention can also be used for the treatment of polyinfection, comprises dissimilar gram positive bacteriums, perhaps comprises Gram-positive and gram negative bacterium.The infection of these types comprises in the abdomen to be infected and obstetrics/gynecological infection.Method of the present invention can also be used for the treatment of such infection, comprises that without limitation Sepsis in endocarditis, ephritis, septic arthritis, the abdomen, B﹠J infect and osteomyelitis.In preferred embodiment, any above-mentioned disease can be used according to lipopeptid compound of the present invention or its pharmaceutical composition and be treated.

When implementing method of the present invention, can also give one or more other biocides, for example antibacterial agent (microbiotic) or anti-mycotic agent.On the one hand, when this method of enforcement, can give more than one according to lipopeptid compound of the present invention.In another embodiment, when this method of enforcement, can give according to lipopeptid compound of the present invention and another kind of lipopeptid compound, for example daptomycin.

Can comprise penicillins and relevant medicine without limitation with the antibacterial agent and the classification thereof of The compounds of this invention co-administered, carbon penicillin alkene class, cephalosporins and relevant medicine, aminoglycosides, bacitracin, linear gramicidins, mupirocin, paraxin, thiamphenicol, Sodium Fusidate, lincomycin, clindamycin, Macrolide, Vulkamycin. PA-93, polymyxins, rifomycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramin, antifol, comprise sulfamido, trimethoprim and combination thereof and Pyrimethamine hcl, the synthetic antiseptic-germicide, comprise itrofurans, hexamine mandelate and methenamine hippu, nitro glyoxaline, quinolones, fluoroquinolones, the vazadrine, Tibutol, pyrazinoic acid amide, right-aminosallcylic acid (PAS), seromycin, capromycin, ethionamide, Protionamide, Thioacetazone, Viothenate, everninomicin, glycopeptide, glycylcylcline, ketolides oxazolidone; Imipenum, amikacin, netilmicin, phosphonomycin, gentamicin, ceftriaxone, Ziracin, LY 333328, CL 331002, HMR 3647, Linezolide, Synercid, aztreonam, metronidazole, epiroprim, OCA-983, GV-143253, Sanfetrinem sodium, CS-834, biapenem, A-99058.1, A-165600, A-179796, KA 159, Dynemicin A, DX 8739, DU 6681; Cefluprenam, ER 35786, Cefoselis, Sanfetrinem celexetil, HGP-31, cefpirome, HMR-3647, RU-59863, Mersacidin, KP 736, Rifalazil; Kosan, AM 1732, MEN10700, Lenapenem, BO 2502A, NE-1530, PR39, K130, OPC 20000, OPC 2045, Veneprim, PD 138312, PD 140248, CP 111905, sulopenem, ritipenem acoxyl, RO-65-5788, Cyclothialidine, Sch-40832, SEP-132613, micacocicin A, SB-275833, SR-15402, SUN A0026, TOC 39, carumonam, Cefozopran, cefetamet pivalyl oxygen formyl and T3811.

In preferred embodiment, can comprise imipenum, amikacin, netilmicin, phosphonomycin, gentamicin, ceftriaxone, teicoplanin, Ziracin, LY 333328, CL 331002, HMR3647, Linezolide, Synercid, aztreonam and metronidazole without limitation with the antibacterial agent of compound co-administered according to the present invention.

Can comprise Caspofungen, Voriconazole, Sertaconazole, IB-367, FK-463, LY-303366, Sch-56592, Sitafloxacin, DB-289, polyenoid class, for example amphotericin, nystatin, Primaricin with the anti-mycotic agent of compound co-administered according to the present invention without limitation; Azoles system, for example fluconazole, itraconazole and KETOKONAZOL; Propylamine, for example naftifungin and Terbinafine; With antimetabolic product, for example flucytosine.Other anti-mycotic agents comprise those among the Drug Discovery Today 5:25-32 (2000) such as being disclosed in Fostel without limitation, are incorporated herein by reference.The disclosed antifungal compound of Fostel comprises Corynecandin, Mer-WF3010, Fusacandins, Artrichitin/LL15G256 γ, Sordarins, Cispentacin, Azoxybacillin, Aureobasidin and Khafrefungin.

Can be with lipopeptid compound according to present method administration until eradicating or reducing infectation of bacteria.In one embodiment, with lipopeptid compound administration 3 days to 6 months.In preferred embodiment, with lipopeptid compound administration 7 to 56 days.In preferred embodiment, with lipopeptid compound administration 7 to 28 days.So preferred embodiment in, with lipopeptid compound administration 7 to 14 days.Time that can the lipopeptid compound administration is longer or shorter, so do if desired.

Lipopeptid compound synthetic universal program

The lipopeptid compound of formula I can as described belowly be prepared.Lipopeptid compound of the present invention can use daptomycin to be prepared by semisynthesis as raw material, perhaps can be prepared by total synthesis method.

About semisynthesis according to the present invention, daptomycin can be prepared according to any means known in the art.For example referring to United States Patent (USP) 4,885,243 and 4,874,843.Can use the acidylate state of daptomycin, perhaps can slough acyl group before use, as described herein.Daptomycin can utilize actinoplanes utahensis (Actinoplanes utahensis) to slough acyl group, and as United States Patent (USP) 4,482,487 is described.Select as an alternative, daptomycin can followingly be sloughed acyl group:

With daptomycin (5.0g) water-soluble (25ml), transfer to pH 9 with 5M sodium hydroxide.Add di-tert-butyl dicarbonic acid ester (1.5g), regulate mixture to keep pH 9, until react completely (4 hours) with 5M sodium hydroxide.Regulate pH to 7, mixture is loaded onto Bondesil 40 μ C8 resin columns.Wash pillar with water, with methyl alcohol eluted product from pillar.Evaporation methyl alcohol obtains the daptomycin that BOC-protects, and is yellow powder.

Produce the deacylase prepared product from the shallow Streptomyces glaucoviolaceus of reorganization (Streptomyces lividans) of expressing the actinoplanes utahensis deacylase.Under pH 7-8, ethylene glycol (the 400 μ l) solution of enzyme is joined in water (100ml) solution of daptomycin (1g) of BOC-protection.Be incubated after 72 hours, mixture is loaded onto Bondesil 40 μ C8 resin columns.Wash pillar with water, with the water eluted product from pillar that contains 10% acetonitrile.Evaporate obtains the daptomycin of the BOC-protection of deacylation, is yellow powder.

The kynurenine derivative

Flow process 1

Daptomycin can be converted into like this and carry R ²The analogue that the position is modified, using and transforming aromatic amine such as reagent such as Sodium Nitrite/hydrochloric acid or isovaleronitriles is the diazonium salt Compound I.Utilize chemistry well known by persons skilled in the art then and follow the instruction of disclosure, diazo can be used, obtain derivative compound II, wherein R such as the displacement of reagent such as sodiumazide, potassium ethyl xanthonate or cupric chloride ¹⁹Be defined as preamble.

Flow process 2

In addition, by with trinitride, the normally reaction of sodiumazide, Compound I can be converted into triazo-compound III.Utilize the known chemistry of those of ordinary skills to modify ketone group then, for example reduction, the generation of oxime, ketone acetal turn to leavings group and displacement, obtain formula IV compound, wherein R ¹⁷And R ¹⁸Be defined as preamble.

Flow process 3

Compound IV also can be converted into compound V like this, utilizes the known chemistry of those of ordinary skills, and follows the instruction of disclosure, and the reduction azido-is an amine, for example with triphenyl phosphine and water or such as the reaction of reductive agents such as sodium borohydride, wherein R ¹⁷And R ¹⁸Be defined as preamble.

Flow process 4

In addition, by the reductive action of Hypophosporous Acid, 50, Compound I can be converted into compound VI.Utilize then be similar to flow process 2 used, the known chemistry of those of ordinary skills, can modify ketone group, wherein R ¹⁷And R ¹⁸Be defined as preamble.

Ornithine derivative

Flow process 1

Daptomycin can be converted into like this and carry R ¹The analogue that the position is modified, with the aromatic amine agent treated of ornithine, for example isocyanic ester, lsothiocyanates, activatory ester, acyl chlorides, SULPHURYL CHLORIDE or activatory sulphonamide, the heterocycle that carries easy displacement group, imido-ester, lactone perhaps reduce with aldehyde, obtain compound VIII, wherein R ¹Be defined as preamble.

The tryptophane sulfonamide derivatives

Flow process 1

Daptomycin can be converted into Compound I X like this, at first uses well known by persons skilled in the art, suitable amido protecting group (P) protected bird propylhomoserin amine, and follows the instruction of disclosure.Use then can the deacylation daptomycin enzyme remove decyl side chain on the tryptophane, for example above-mentioned.

Flow process 2

The tryptophane amine of Compound I X can be modified with reagent, for example isocyanic ester, lsothiocyanates, activatory ester, acyl chlorides, SULPHURYL CHLORIDE or activatory sulphonamide, the heterocycle that carries easy displacement group, imido-ester, lactone, perhaps, obtain compounds X with the aldehyde reduction.According to program well known by persons skilled in the art and follow disclosure of the present invention, can remove to protect compounds X, wherein R is defined as preamble.

Can unite independently carry out above-mentioned to ornithine amine R ¹, tryptophane amine R or kynurenine side chain R ²Modification, obtain in addition nearly all three adorned compounds in position.In order to realize these modifications, has some functionality in the necessary protection molecule.Protect these functionality should be in those skilled in the art's expertise, and follow disclosure of the present invention.For example referring to Greene, ibid.

The solid carrier of lipopeptid compound is synthetic

Can be in the alternate invention embodiment, can be on solid carrier the lipopeptid compound of synthesis type I, as described below.In step 1, make β MeGlu (the OH)-O allyl ester and the resin coupling that is fit to of suitable N-protected, obtain compounds X II.Remove to protect the amino of compounds X II, make seryl derivative (A1) coupling of this amino and due care then, obtain compounds X III, wherein P is the blocking group that is fit to.Repeat this peptide coupling process, just go to protect alpha-amino group then with the amino acid coupling of due care, until the amino acid of desired number with the resin coupling.Under show in the flow process, coupling 11 amino acid, obtain compounds X IV.Add activatory R radicals R * to compounds X IV, obtain compounds X V.In step 4, make compounds X V cyclisation, obtain compounds X VI.In step 5, remove compounds X VI subsequently, obtain lipopeptid compound XVII from resin.

The complete synthesis flow process of lipopeptid compound

A wherein ¹Be the serine derivative of due care, wherein R ³¹Be hydroxy-protective group that be fit to, cleavable, as described below.

A wherein ²And A ⁷Be the glycine derivative of due care, as described below.

A wherein ³, A ⁵And A ⁹Be the aspartame of due care, as described below, wherein ²⁸R, ²⁹R and ³⁰R is the blocking group of cleavable, is preferably the tertiary butyl.

A wherein ⁴Be the alanine derivatives of due care, as described below.

A wherein ⁶Be the ornithine derivative of due care, as described below, or deutero-ornithine, wherein * R ¹Be R as previously described ¹Or R ¹The protection form, through subsequently go the protection will generate R ¹

A wherein ⁸Be the depsipeptide of due care, as described below, Y is a blocking group, can be at other used blocking groups, be cracking under the complete condition of Alloc; * R wherein ²Be R as previously described ²Or R ²The protection form, through subsequently go the protection will generate R ²Preferably, * R ²Be the kynurenine side chain of kynurenine or replacement, most preferably

A wherein ¹⁰Be the asparagine derivative of due care, as described below.

A wherein ¹¹Be the tryptophan derivative of due care, as described below, * R wherein ³⁷Be hydrogen or suitable blocking group, be preferably tertbutyloxycarbonyl.

Those skilled in the art will appreciate that amino and side chain functionalities all must they with before the peptide chain that is prolonging is connected by due care.The blocking group that is fit to can be any group of peptide synthetic that can be used for known in the art.This class blocking group pairing is known.For example referring to Novabiochem Catalog and Peptide Synthesis Handbook (1999), " synthetic note " among the S1-S93 and the reference of wherein quoting.Follow the application's disclosure, the selection of blocking group and using method thereof will be well known by persons skilled in the art.

Those skilled in the art also will appreciate that, the selection of blocking group will cause or not cause blocking group in finally cracked cracking simultaneously from the resin of peptide on the side chain functionalities, and this will obtain natural amino-acid functional degree or its protected derivative respectively.

Following universal program is synthetic in order to the solid carrier of illustration formula I compound.

Step 1: make β MeGlu (the OH)-O allyl ester and the resin coupling of suitable N-protected

To respectively be β MeGlu (the OH)-O allyl ester, 1 of the suitable N-protected of five molar equivalents about resin, 3-DIC (DIC) and 1-hydroxyl-7-azepine benzotriazole (HOAt) be at dimethyl formamide (DMF; The 5mg/kg resin) stirred 30 minutes in.Add suitable functionalized resin or solid carrier,, the gained suspension was stirred 16 hours such as but not limited to Wang, Safety Catch, Rink, Knorr, PAL or PAM resin.β MeGlu (OH)-O allyl ester with resin-N-protected filters then, and drying repeats coupling.The felicity condition that provides in the coupling step below utilizing is removed the N-protected group.

Step 2 (A): the general coupling cycle of amino acid and N-9-fluorenylmethyloxycarbonyl (Fmoc) blocking group

To respectively be that Fmoc amino acid, DIC and the HOAt (0.5 mole of DMF solution) of the due care of five molar equivalents joins among resin-AA about resin-AA (wherein resin-AA is defined as being connected with the resin of the amino acid chain that is prolonging), and the DMF that adds capacity be to reach working volume.Mixture was shaken one hour, filter, repeat coupling.After the coupling for the second time,,, use the DMF washed twice again with methanol wash twice with resin DMF washed twice.New link coupled amino acid A ^1-11The Fmoc group be de-protected like this, resin product was stirred five minutes in the N-crassitude solution that contains 20% piperidines of a working volume, filter resin, resin was stirred 20 minutes in containing the N-crassitude of 20% piperidines once more.With resin DMF washed twice,, use the DMF washed twice again with methanol wash twice.

Step 2 (B): the general coupling cycle of amino acid and N-tertbutyloxycarbonyl (N-Boc) blocking group

To respectively be that N-Boc amino acid, DIC and the HOAt (0.5 mole of DMF solution) of the due care of five molar equivalents joins among resin-AA about resin-AA, and the DMF that adds capacity be to reach working volume.Mixture was shaken one hour, filter, repeat coupling.After the coupling for the second time,,, use the DMF washed twice again with methanol wash twice with resin DMF washed twice.New link coupled amino acid A ^1-11The Boc group be de-protected like this, with the CH of resin product at a working volume ₂Cl ₂: trifluoroacetic acid (TFA) stirred 15 minutes in 1: 1, filtered, at the CH of a working volume ₂Cl ₂: TFA1: stirred other 15 minutes in 1.With the CH of resin with excessive diisopropylethylamine (DIPEA) ₂Cl ₂Solution washing neutralizes, and uses the DMF washed twice then, with methanol wash twice, uses the DMF washed twice again.

Step 3: terminal amine end capping

To join among the resin XIV about a working volume DMF solution that contains R* reagent (for example activatory ester, isocyanic ester, lsothiocyanates, acid anhydrides, acyl chlorides, chloro-formic ester or its reactive salts) that is fit to of resin XV ten molar equivalents, stirred 25 hours.With gained resin XV DMF washed twice,, use the DMF washed twice again with methanol wash twice.

Step 4: cyclisation

Dried resin XV is placed under the argon atmospher, with the Pd (PPh of 125mg/0.1mmol peptide substrates ₃) ₄CH at the 1ml/0.1mmol peptide substrates ₂Cl ₂: acetate: the solution-treated in the N-methylmorpholine 40: 2: 1.Mixture was stirred 3 hours at ambient temperature, filter, use the DMF washed twice,, use the DMF washed twice again with methanol wash twice.To respectively be that the DIC of five molar equivalents and HOAt (0.5 mole of DMF solution) join resin and dash about resin, and the DMF that adds capacity be to reach working volume.To react system and shake 17 hours, filter, use the DMF washed twice,, use the DMF washed twice again, obtain resin XVI with methanol wash twice.

Step 5: the cracking of lipopeptid with separate

Go up required lipopeptid of cracking and separation from resin XVI, obtain wherein R ²⁷Be OH or NH ₂Compound.If utilize the Fmoc chemistry, so dried resin is suspended in the CH of 1ml/0.1mmol peptide substrates ₂Cl ₂: TFA: dithioglycol (EDT): tri isopropyl silane (TIS) 16: 22: 1: in 1, stirred at ambient temperature 6-8 hour.With resin filter, with isopyknic cold TFA washing, merging filtrate, vapourisation under reduced pressure.Add diethyl ether then and be settled out crude product XVII, centrifugation.This product can further pass through preparation type reversed-phase HPLC purifying.

If utilize the N-Boc chemistry, so dried resin is suspended in hydrogen fluoride (HF): phenylmethylether: dimethyl sulphide (DMS) stirred 2 hours down at 0 ℃ in 10: 1: 1.Under nitrogen gas stream, evaporate volatile matter.Then resin is extracted with TFA, filter, use the TFA washed twice, merge TFA filtrate, vapourisation under reduced pressure.Add diethyl ether then and be settled out crude product, centrifugation.This product can further pass through preparation type reversed-phase HPLC purifying.

If resin is Safety Catch resin, R so ²⁷=OR or NRH.Dried resin XVI is suspended in N-crassitude (NMP) or the dimethyl sulfoxide (DMSO) (DMSO) (8ml/g resin), adds (about the resin quid pro quo) 5 equivalent DIPEA and (about the resin quid pro quo) 24 equivalent iodomethyl cyanide or bromoacetonitriles.Suspension was stirred 24 hours under envrionment temperature and inert atmosphere.With resin filter, with tetrahydrofuran (THF) (THF) and DMSO washing.About ester, then with resin with the THF solution-treated of (about resin quid pro quo 20 equivalents) alcohol, oxyhydroxide or alcoholate 20 hours.With resin filter, with THF and water washing, merging filtrate, vapourisation under reduced pressure.Add diethyl ether and be settled out crude product, centrifugation.This product can further pass through preparation type reversed-phase HPLC purifying.About acid amides, then under gentle reflux and inert atmosphere, with resin with the THF solution-treated of (about resin quid pro quo 20 equivalents) primary amine or secondary amine 12-40 hour.With resin filter, with THF and water washing, merging filtrate, vapourisation under reduced pressure.Add diethyl ether then and be settled out crude product, centrifugation.This product can further pass through preparation type reversed-phase HPLC purifying.

In order to understand the present invention more fully, set forth the following example.These embodiment are only for illustrating, in any case also be not interpreted as limiting scope of invention.

Embodiment 1: the preparation of compound 1,19,40-44,49,72-74,100,115-116 and 123-125

With daptomycin (5.0g) water-soluble (25ml), 5M sodium hydroxide transfers to pH 9.Add di-tert-butyl dicarbonic acid ester (1.5g), the pH that keeps mixture with 5M sodium hydroxide is 9, until react completely (4 hours).Regulate pH to 7, mixture is loaded onto Bondesil 40 μ C8 resin columns.Wash pillar with water, with methyl alcohol eluted product from pillar.Evaporation methyl alcohol obtains the daptomycin (5.08g) that BOC-protects, and is yellow powder.

Produce the deacylase prepared product from the shallow Streptomyces glaucoviolaceus of the reorganization of expressing the actinoplanes utahensis deacylase.Under pH 7-8, ethylene glycol (the 400 μ l) solution of enzyme is joined in water (100ml) solution of daptomycin (1g) of BOC-protection.Be incubated after 72 hours, mixture is loaded onto Bondesil 40 μ C8 resin columns.Wash pillar with water, with the water eluted product from pillar that contains 10% acetonitrile.Evaporate obtains the daptomycin (440mg) of the BOC-protection of deacylation, is yellow powder.

At room temperature, daptomycin (100mg) and the octyl isocyanate (20 μ l) with the BOC-of deacylation protection stirred 24 hours in anhydrous dimethyl formamide (5ml).Evaporating solvent obtains the yellow powder resistates, will stir 2 hours in its mixture at trifluoroacetic acid/dichloromethane/tri isopropyl silane/dithioglycol (11/8/0.5/0.5) (2ml).Evaporation obtains yellow residue, process preparation HPLC purifying on IBSIL-C8 5 μ 250 * 20.2mm post.Pillar is used the 5mM ammonium phosphate buffer solution elution that contains 36% acetonitrile by 20ml/min.The part that lyophilize is collected.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns.Pillar is washed with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 1, is faint yellow solid (30mg).

Follow the as above instruction of routine described disclosure, and carry out suitable reagent and replace, those of ordinary skills can prepare compound 19,40-44,49,72-74,100,115-116 and 123-125 in a comparable manner.

Embodiment 1a: the preparation of compound 18,37-39,45-47

At room temperature, daptomycin (100mg) and the 4-chloro-biphenylacetic acid pentafluorophenyl group ester (32mg) with the BOC-of deacylation protection stirred 2 days in anhydrous dimethyl formamide (3ml).Mixture is loaded onto IBSIL-C8 5 μ 250 * 20.2mm post, use the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains the intermediate that Boc-protects, and is faint yellow solid (41mg).

At room temperature, the intermediate (40mg) with the Boc-protection stirred 2 hours in trifluoroacetic acid (2ml) and phenylmethylether (0.1ml).Under reduced pressure remove and desolvate, obtain resistates, load onto IBSIL-C8 5 μ 250 * 20.2mm post, use the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 18, is faint yellow solid (10mg).

Follow the as above instruction of routine described disclosure, and carry out suitable reagent and replace, those of ordinary skills can prepare compound 37-39 and 45-47 in a comparable manner.

Embodiment 1b: compound 110,112,109 and 111 preparation

According to embodiment 1 and 1a, from the daptomycin α of the Boc-of deacylation protection, β-tridecylene acyl group penta fluoro benzene phenolic ester prepares the daptomycin α of Boc-protection, β-tridecylene acid amides (compound 110).At room temperature, compound 110 (0.21g) was stirred 3 hours in anhydrous methylene chloride (8ml), trifluoroacetic acid (11ml) and dithioglycol (0.25ml).Under reduced pressure concentrate, obtain light brown oil, purifying on IBSIL-C8 5 μ 250 * 20.2mm post, by 25ml/min with the 5mM ammonium phosphate buffer solution for gradient elution that contains the 30-60% acetonitrile 40 minutes.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 112 (53.8mg), is faint yellow solid.

Follow the as above instruction of routine described disclosure, and carry out suitable reagent and replace, those of ordinary skills can prepare compound 109 and 111 in a comparable manner.

Embodiment 2: the preparation of compound 2

Anhydrous dimethyl formamide (3ml) solution of dodecyl isocyanic ester (0.507g) is joined in anhydrous dimethyl formamide (30ml) solution of daptomycin (3.14g) of Boc-protection of deacylation.Mixture is stirred under room temperature and nitrogen.After 7 hours, purified mixture on Bondesil40 μ C8 resin column is with 10% acetonitrile-water, use 50% acetonitrile-water wash-out again.Required part lyophilize obtains the daptomycin dodecyl urea (3.38g) that Boc-protects, and is faint yellow fine hair shape solid.

At room temperature, the daptomycin dodecyl urea (2.42g) with the Boc-protection stirred 4 hours in anhydrous methylene chloride (20ml), trifluoroacetic acid (22ml) and dithioglycol (0.5ml).Mixture is concentrated into light brown oil, then with methyl alcohol and diethyl ether development.After mixture is centrifugal, yellow residue is loaded onto IBSIL-C8 5 μ 250 * 20.2mm post, by 25ml/min with the 5mM ammonium phosphate buffer solution for gradient elution 40 minutes that contains the 30-60% acetonitrile.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 2 (2.53g), is faint yellow solid.

Compound 2a: the preparation of compound 48

Anhydrous dimethyl formamide (1ml) solution of undecyl isocyanic ester (0.197g) is joined in anhydrous dimethyl formamide (20ml) solution of daptomycin (1.62g) of Boc-protection of deacylation.Mixture was stirred 7 hours under room temperature and nitrogen.Purified mixture on Bondesil40 μ C8 resin column then is with 10% acetonitrile-water, use 50% acetonitrile-water wash-out again.Required part lyophilize obtains the daptomycin undecyl urea (1.58g) that Boc-protects, and is faint yellow fine hair shape solid.

The daptomycin undecyl urea (1.58g) of Boc-protection was stirred 4 hours in anhydrous methylene chloride (20ml), trifluoroacetic acid (22ml) and 5% phenylmethylether, be evaporated to dried then.Resistates is loaded onto IBSIL-C8 5 μ 250 * 20.2mm post, by 25ml/min with the 5mM ammonium phosphate buffer solution for gradient elution 40 minutes that contains the 30-60% acetonitrile.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 48 (136.5mg), is faint yellow solid.

Embodiment 2b: compound 117 and 118 preparation

Anhydrous dimethyl formamide (0.2ml) solution of isocyanic acid nonyl ester (40.6mg) is joined in anhydrous dimethyl formamide (2ml) solution of daptomycin (313.2mg) of Boc-protection of deacylation.Mixture is stirred under room temperature and nitrogen.After 7 hours, purified mixture on IBSIL-C8 5 μ 250 * 20.2mm post, by 25ml/min with the 5mM ammonium phosphate buffer solution for gradient elution 40 minutes that contains the 30-60% acetonitrile.Collected the part that contains required compound, lyophilize at 21 minutes.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 117 (158.8mg), is faint yellow solid.

At room temperature, compound 117 (58.9mg) was stirred 2 hours in anhydrous methylene chloride (5ml), trifluoroacetic acid (2ml) and dithioglycol (0.05ml), be evaporated to dried then.Resistates is loaded onto IBSIL-C8 5 μ 250 * 20.2mm post, by 25ml/min with the 5mM ammonium phosphate buffer solution for gradient elution 40 minutes that contains the 30-60% acetonitrile.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 118 (11.2mg), is faint yellow solid.

Embodiment 2c: compound 119 and 120 preparation

Anhydrous dimethyl formamide (0.2ml) solution of isocyanic acid decyl ester (0.44g) is joined in anhydrous dimethyl formamide (20ml) solution of daptomycin (3.13g) of Boc-protection of deacylation.Mixture is stirred under room temperature and nitrogen.After 7 hours, purified mixture on Bondesil 40 μ C8 resin columns is with 10% acetonitrile-water, use 50% acetonitrile-water wash-out again.Required part lyophilize obtains compound 119 (1.73g), is faint yellow solid.

At room temperature, compound 119 (1.73g) was stirred 4 hours in anhydrous methylene chloride (20ml), trifluoroacetic acid (22ml) and dithioglycol (0.5ml), be evaporated to dried then.Resistates with the development of methyl alcohol and diethyl ether, is loaded onto IBSIL-C8 5 μ 250 * 20.2mm post then, by 25ml/min with the 5mM ammonium phosphate buffer solution for gradient elution that contains the 30-60% acetonitrile 40 minutes.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 120 (359.8mg), is faint yellow solid.

Embodiment 3: compound 3,5-6,8-13,20-24,34-36,50,71 and 75 preparation

At room temperature, daptomycin (250mg) and N-tBoc-L-tryptophane-right-nitrophenyl ester (144mg) were stirred 2 days in anhydrous dimethyl formamide (3ml).Mixture is loaded onto IBSIL-C8 5 μ 250 * 20.2mm post, use the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains N-Boc tryptophane daptomycin, is faint yellow solid (130mg).

Produce the deacylase prepared product from the shallow Streptomyces glaucoviolaceus of the reorganization of expressing the actinoplanes utahensis deacylase.Ethylene glycol (the 400 μ l) solution of this enzyme is joined in hplc grade water (20ml) solution of N-Boc tryptophane daptomycin (100mg).PH to 8.5 with sodium hydroxide (1M) regulator solution.Mixture was stirred 24 hours.Mixture is loaded onto C8 resin stick harness, wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains resistates, and last IBSIL-C8 5 μ 250 * 20.2mm post is used the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporate methyl alcohol, obtain the N-Boc tryptophane daptomycin of deacylation, be faint yellow solid (42mg).

At room temperature, the N-Boc tryptophane daptomycin (20mg) with deacylation stirs in anhydrous dimethyl formamide (2ml).In solution, add undecyl isocyanic ester (2.25mg).After stirring 24 hours at ambient temperature, with mixture water (10ml) dilution, last Bondesil40 μ C8 resin column washes with water, uses methanol-eluted fractions.Evaporate methyl alcohol, obtain the undecyl urea of N-Boc tryptophane daptomycin, be faint yellow solid (21mg).

At room temperature, N-Boc tryptophane daptomycin undecyl urea (21mg) was stirred 2 hours in trifluoroacetic acid (2ml) and phenylmethylether (0.1ml).Under reduced pressure remove and desolvate, obtain resistates, load onto IBSIL-C8 5 μ 250 * 20.2mm post, use the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 3, is faint yellow solid (0.8mg).

In a comparable manner, and carry out suitable reagent and replace, can as above routine described preparation compound 5-6,8-13,20-24,34-36,50,71 and 75.

Embodiment 3a: the preparation of compound 7

At room temperature, the N-Boc tryptophane daptomycin (50mg) with deacylation stirs in anhydrous dimethyl formamide (2ml) with aldehyde C-9 (4.1mg).In solution, add sodium triacetoxy borohydride (3.6mg).Mixture was stirred 24 hours, load onto IBSIL-C8 5 μ 250 * 20.2mm post then, use the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains nonyl amino N-Boc tryptophane daptomycin, is faint yellow solid (14mg).

At room temperature, nonyl amino N-Boc tryptophane daptomycin (14mg) was stirred 2 hours in trifluoroacetic acid (2ml) and phenylmethylether (0.1ml).Under reduced pressure remove and desolvate, obtain resistates, load onto IBSIL-C8 5 μ 250 * 20.2mm post, use the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 7, is faint yellow solid (5mg).

Embodiment 3b: the preparation of compound 17

At room temperature, the N-Boc tryptophane daptomycin (50mg) with deacylation stirs in anhydrous dimethyl formamide (2ml).In solution, add dodecyl isocyanic ester (6.0mg).Mixture was stirred 24 hours.Mixture is loaded onto IBSIL-C8 5 μ 250 * 20.2mm post, use the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil40 μ C8 resin column washes with water, uses methanol-eluted fractions.Evaporate methyl alcohol, obtain the dodecyl urea of N-Boc tryptophane daptomycin, be faint yellow solid (27mg).

At room temperature, N-Boc tryptophane daptomycin dodecyl urea (25mg) was stirred 2 hours in trifluoroacetic acid (2ml) and phenylmethylether (0.1ml).Under reduced pressure remove and desolvate, obtain resistates, load onto IBSIL-C8 5 μ 250 * 20.2mm post, use the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 17, is faint yellow solid (4.3mg).

Embodiment 4: compound 69,25,56-58,62-64,70,106 and 108 preparation

At room temperature, will utilize octyl isocyanate anhydrous dimethyl formamide (2ml), to stir 2 days according to embodiment 1 and 1a from the daptomycin synthetic daptomycin octyl group urea (60mg) and the N-tBoc-L-tryptophane-right-nitrophenyl ester (31mg) of the Boc-protection of deacylation.Mixture is loaded onto IBSIL-C8 5 μ 250 * 20.2mm post, use the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporate methyl alcohol, obtain the intermediate of acidylate, be faint yellow solid (29mg).

At room temperature, the intermediate (25mg) with acidylate stirred 2 hours in trifluoroacetic acid (2ml) and phenylmethylether (0.1ml).Vapourisation under reduced pressure obtains resistates, loads onto IBSIL-C8 5 μ 250 * 20.2mm post, uses the 5mM ammonium phosphate buffer solution elution that contains 37% acetonitrile by 20ml/min.Collection contains the part of required compound, lyophilize.With cryodesiccated resistates water-soluble (5ml), last Bondesil 40 μ C8 resin columns wash with water, use methanol-eluted fractions.Evaporation methyl alcohol obtains compound 69, is faint yellow solid (5mg).

In a comparable manner, and carry out suitable reagent and replace, those of ordinary skills can as above routine described preparation compound 25,56-58,62-64,70,106 and 108.

Embodiment 4a: compound 89,76-78,87-88 and 113

To utilize the dodecyl isocyanic ester from anhydrous dimethyl formamide (1.0ml) solution of the daptomycin synthetic daptomycin dodecyl urea (200mg) of the Boc-of deacylation protection and 2-imidazole formaldehyde (21mg), to add sodium triacetoxy borohydride (152mg) according to embodiment 1 and 1a.Mixture was at room temperature stirred 24 hours, pass through the preparation HPLC purifying then.Mixture is loaded onto IBSIL-C8 5 μ 250 * 20.2mm post, by 25ml/min with the 5mM ammonium phosphate buffer solution for gradient elution 30 minutes that contains the 30-60% acetonitrile.Collected the part that contains required compound, lyophilize at 21 minutes.With cryodesiccated resistates water-soluble (3ml), last Bondesil 40 μ C8 resins (500mg) plug.Water (10ml) washing Bondesil resin is used methyl alcohol (10ml) eluted product then.Evaporation methyl alcohol obtains compound 89, is faint yellow solid (15mg).

Follow the as above instruction of routine described disclosure, and carry out suitable reagent and replace, those of ordinary skills can prepare compound 76-78,87-88 and 113 in a comparable manner.

Embodiment 4b: the preparation of compound 114

To utilize the undecyl isocyanic ester from anhydrous dimethyl formamide (0.6ml) solution of the daptomycin synthetic daptomycin undecyl urea (100mg) of the Boc-of deacylation protection and 5-methoxyl group indole-3-formaldehyde (11mg), to add sodium triacetoxy borohydride (76mg) according to embodiment 1 and 1a.Mixture was at room temperature stirred 24 hours, pass through the preparation HPLC purifying then.Mixture is loaded onto IBSIL-C8 5 μ 250 * 20.2mm post, by 25ml/min with the 5mM ammonium phosphate buffer solution for gradient elution 30 minutes that contains the 30-60% acetonitrile.Collected the part that contains required compound, lyophilize at 21 minutes.With cryodesiccated resistates water-soluble (2ml), last Bondesil 40 μ C8 resins (500mg) plug.Water (10ml) washing Bondesil resin is used methyl alcohol (10ml) eluted product then.Evaporation methyl alcohol obtains compound 114, is faint yellow solid (10mg).

Embodiment 5

According to the described standard program of standard committee of national clinical labororatory (NCCLS file M7-A5, Vol.20, No.2,2000), the compound of experimental evidence formula I is to the antimicrobial acivity of one group of biology, but all tests are all carried out under 37 ℃.Compound is dissolved in 100% dimethyl sulfoxide (DMSO), in the microorganism growth substratum, is diluted to end reaction concentration (0.1 μ g/ml-100 μ g/ml).In all cases, the ultimate density of the dimethyl sulfoxide (DMSO) that is incubated with cell is less than or equal to 1%.About the calculating of minimum inhibition concentration (MIC), the compound that 2-is doubly diluted joins in the aperture of microtitration ware, wherein contains 5 * 10 ⁴Individual bacterial cell, (Mueller-Hinton meat soup is supplemented with 50mg/L Ca to substratum ²⁺) final volume be 100 μ L.Utilize business-like plate reader to measure the bacterial cell optical density(OD) (OD) of reflection bacterial cell growth and propagation.The MIC value is defined as suppressing to supply the minimum compound concentration of examination biological growth.The MIC of representative compounds of the present invention (μ g/ml) value is listed in the Table VI.

Embodiment 6

The antibacterial activity in vivo of compound 2 (seeing Table IV) is to establish like this, and the female CD-1 mouse of usefulness X-1497 tolerance streptococcus aureus (MRSA) inoculum intraperitoneal infection body weight 19-23g (Charles River Lab, MA).This inoculum prepares from X-1497 tolerance streptococcus aureus (ATCC 43300).The MRSA inoculum was cultivated 18 hours in 37 ℃ of Mueller-Hinton (MH) meat soup.Press the optical density(OD) (OD that dilution overnight incubation after measures 600nm under at 1: 10 ₆₀₀).With bacterium (8 * 10 ⁸Cfu) join in the 20ml phosphate buffered saline (PBS) (Sigma P-0261), wherein contain 6% hog gastric mucin (SigmaM-2378).To 1-5 treated animal injection 0.5ml inoculum, be equivalent to 2 * 10 ⁷The cfu/ mouse, this is to cause being untreated the dosage of animal ~ 100% death.Do not accept inoculum for the 6th group.

Test compound (10mg) is dissolved in 10.0ml 50mM phosphate buffered saline buffer, obtains the solution (pH=7.0) of 1mg/ml.This solution continuously with 4 times (1.5ml to 6.0ml) of carrier dilution, is obtained 0.25,0.063 and 0.016mg/ml solution.All solution filter with 0.2 μ m Nalgene injection filter.After microbionation,, give test compound, be respectively 10.0,2.5,0.63 and 0.16mg/kg to the 2nd to 5 group of sc immediately to the 1st treated animal subcutaneous (sc) injection damping fluid (not having test compound).The 6th treated animal only sc is accepted 10mg/kg compound 2.4 hours repeat these injections once after each winding kind.Each volume injected is the every kg body weight of 10ml.The result of efficacy test is summarised in the Table IV in the body, and it provides compound 2 gained results' representative example.50% effective dose (ED ₅₀) be on the basis of 7 days mouse quantity of survival after the inoculation, to calculate.The ED of other representative compounds of the present invention ₅₀The mg/kg ordered series of numbers in Table V.

Table V

Group	Mouse #	Inoculation	Handle	Survival (7 days)
Group	Mouse #	Inoculation	Handle	Survival (7 days)	1	?5	????MRSA#43300?2×10 ⁷The cfu/ mouse	Phosphate buffer 1 0ml/kg, s.c.x2	????0/5
2	?5	????MRSA#43300?2×10 ⁷The cfu/ mouse	Compound 2 10mg/kg, s.c.x2	????5/5	1	?5	????MRSA#43300?2×10 ⁷The cfu/ mouse	Phosphate buffer 1 0ml/kg, s.c.x2	????0/5
2	?5	????MRSA#43300?2×10 ⁷The cfu/ mouse	Compound 2 10mg/kg, s.c.x2	????5/5	3	?5	????MRSA#43300?2×10 ⁷The cfu/ mouse	Compound 2 2.5mg/kg, s.c.x2	????5/5
4	?5	????MRSA?#43300?2×10 ⁷The cfu/ mouse	Compound 2 0.63mg/kg, s.c.x2	????5/5	3	?5	????MRSA#43300?2×10 ⁷The cfu/ mouse	Compound 2 2.5mg/kg, s.c.x2	????5/5
4	?5	????MRSA?#43300?2×10 ⁷The cfu/ mouse	Compound 2 0.63mg/kg, s.c.x2	????5/5	5	?5	????MRSA?#43300?2×10 ⁷The cfu/ mouse	Compound 2 0.16mg/kg, s.c.x2	????1/5
6	?5	Do not have	Compound 2 10mg/kg, s.c.x2	????5/5	5	?5	????MRSA?#43300?2×10 ⁷The cfu/ mouse	Compound 2 0.16mg/kg, s.c.x2	????1/5

The ED of compound 2 ₅₀Be 0.43mg/kg as calculated.

Measure the ED of other The compounds of this invention in a comparable manner ₅₀

Table VI

Compound #	MIC (μ g/ml) streptococcus aureus	MIC (μ g/ml) enterococcus faecalis	??ED ₅₀??(mg/kg)
Compound #	MIC (μ g/ml) streptococcus aureus	MIC (μ g/ml) enterococcus faecalis	??ED ₅₀??(mg/kg)	??1	??++	????+
??2	??+++	????++	??+++	??1	??++	????+
??2	??+++	????++	??+++	??3	??+++	????+++	??+++
??5	??++	????++		??3	??+++	????+++	??+++
??5	??++	????++		??6	??+
??7	??+	????+		??6	??+
??7	??+	????+		??8	??++	????+
??9	??++	????+		??8	??++	????+
??9	??++	????+		??10	??++	????+
??11	??+	????+		??10	??++	????+
??11	??+	????+		??12	??+	????+
??13	??++	????+		??12	??+	????+
??13	??++	????+		??17	??+++	????+++
??18	??+++	????++	??+++	??17	??+++	????+++
??18	??+++	????++	??+++	??19
??20	??+			??19
??20	??+			??21	??+
??22	??+			??21	??+
??22	??+			??23	??++
??24	??+++	????+		??23	??++
??24	??+++	????+		??25	??++	????+
??34	??+++	????++		??25	??++	????+
??34	??+++	????++		??35	??++	????+
??36	??+			??35	??++	????+
??36	??+			??37	??++	????+
??38	??+++	????++		??37	??++	????+
??38	??+++	????++		??39	??+++	????+++
??40	??+			??39	??+++	????+++
??40	??+			??41
??43				??41

????44	????++	????+
????44	????++	????+		????45	????+++	????++
????46	????++	????+		????45	????+++	????++
????46	????++	????+		????47	????+++	????+++
????48	????+++	????+++	????+++	????47	????+++	????+++
????48	????+++	????+++	????+++	????49	????++	????++
????50	????+++	????++		????49	????++	????++
????50	????+++	????++		????56	????++	????+
????57	????++	????++		????56	????++	????+
????57	????++	????++		????58	????++	????++
????62	????++	????+		????58	????++	????++
????62	????++	????+		????63	????+++	????++
????64	????+++	????++		????63	????+++	????++
????64	????+++	????++		????69	????+++	????+
????70				????69	????+++	????+
????70				????71	????+++	????+
????72	????+++	????+		????71	????+++	????+
????72	????+++	????+		????73	????+++	????++
????74	????+++	????++		????73	????+++	????++
????74	????+++	????++		????75	????+++	????++
????76	????++	????+		????75	????+++	????++
????76	????++	????+		????77	????+++	????+
????78	????++	????+		????77	????+++	????+
????78	????++	????+		????87	????+++	????++
????88	????+++	????++		????87	????+++	????++
????88	????+++	????++		????89	????+++	????+++
????100	????+			????89	????+++	????+++
????100	????+			????106	????++	????+
????108		????++		????106	????++	????+
????108		????++		????109	????++	????+
????110	????+++	????++		????109	????++	????+
????110	????+++	????++		????111	????+++	????++

????112	????+++	????+++
????112	????+++	????+++	????113	????++	????++
????114	????+++	????++++	????113	????++	????++
????114	????+++	????++++	????115	????++	????+
????116	????+++	????++	????115	????++	????+
????116	????+++	????++	????117	????++	????+
????118	????+++	????+++	????117	????++	????+
????118	????+++	????+++	????119	????+++	????++
????120	????+++	????+++	????119	????+++	????++
????120	????+++	????+++	????123	????++
????124	????++	????+++	????123	????++
????124	????++	????+++	????125	????++	????+++

Wherein " +++" represent that the MIC (μ g/ml) of compound is 1 μ g/ml or following, perhaps ED ₅₀Be 1mg/kg or following;

The MIC (μ g/ml) or the ED of " ++ " expression compound ₅₀(mg/kg), but be less than or equal to 10 μ g/ml or 10mg/kg respectively respectively greater than 1 μ g/ml or 1mg/kg;

The MIC (μ g/ml) of "+" expression compound is greater than 10 μ g/ml, perhaps ED ₅₀Greater than 10mg/kg.

All publications and patent application that this specification sheets is quoted all are incorporated herein by reference document, and independently publication or patent application are concrete and separately in conjunction with as a reference as every piece.Although for the clear purpose of understanding, describe aforementioned invention in detail by illustrating with embodiment, but in view of instruction of the present invention, be easy to for those of ordinary skills it is evident that and carry out some change and modification to it, and do not deviate from the spirit or scope of appended claims.

Claims

1, formula (I) compound:

And salt,

Wherein R is:

Wherein n is 0 or 1;

Wherein A is H, NH ₂, NHR ^A, NR ^AR ^B, heteroaryl, cycloalkyl or heterocyclic radical; Or

Wherein if n is 0, then A is selected from addition

With

Its condition is that then A is not if B is that H and X are C=O

(a) by a substituting group NHC (O) R ^DThe pyridyl that replaces, or

If B is that H and n are 0, then A is not H;

R wherein ¹Be:

Wherein m is 0 or 1;

Wherein if m be 0, then A ' be selected from addition by With

The group of forming, wherein each R ⁵⁰-R ⁵³Be independently selected from C ₁-C ₁₅Alkyl;

R wherein ²Be

R wherein ^JAnd R ^KBe independently selected from alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclic radical;

The group of forming; Perhaps

R wherein ¹⁷And R ¹⁸Can constitute together ketone acetal, thioketal,

With

Each R wherein ²²And R ²³Be independently selected from the group of forming by hydrogen and alkyl.

2, the compound of formula (I),

And salt,

Wherein R is:

Wherein n is 0 or 1;

A is an aryl;

R wherein ¹Be:

Wherein m is 0 or 1;

Wherein if m is 0, then A ' is selected from addition With

R wherein ²Be

With

The group of forming; Perhaps

3, the compound of formula (I),

And salt,

Wherein R is:

Wherein n is 0 or 1;

A is alkyl, thiazolinyl, alkynyl, alkoxyl group or aryloxy;

Its condition is that then A is not if B is that H and X are C=O

(a)-(C ₁-C ₁₆Unsubstituted alkyl)-NH ₂

(d)-C ₄-C ₁₈Unsubstituted thiazolinyl;

If B is that H and n are O, then A is not C ₄-C ₁₄Unsubstituted alkyl;

R wherein ¹Be:

Wherein m is 0 or 1;

R wherein ^{A '}With ^{B '}Be independently selected from alkyl, thiazolinyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic radical or carbalkoxy;

Wherein if m is 0, then A ' is selected from addition With

R wherein ²Be

With

The group of forming; Perhaps

4, the compound of formula (I),

And salt,

Wherein R is:

Wherein n is 0 or 1;

B and A constitute 5-7 unit's heterocycle or heteroaryl ring together;

R wherein ¹Be: Wherein X ' and X_ are independently selected from C=O, C=S, C=NH, C=NR ^X, S=O or SO ₂

Wherein m is 0 or 1;

Wherein if m is 0, then A ' is selected from addition With

R wherein ²Be

The group of forming; Perhaps

5, according to the compound of any claim 1-4, wherein R is selected from the group of being made up of following formula:

6, according to the compound of claim 5, wherein R is selected from: With

R wherein ^{4 '}Be selected from alkyl, the phenyl of replacement, heteroaryl, heterocyclic radical, optional substituted (C by alkyl, aryl-replacement ₈-C ₁₄)-straight chained alkyl and

R wherein ⁷It is alkyl.

7, according to the compound of claim 6, wherein R is selected from the group of being made up of following formula:

With

X wherein ³Be chlorine or trifluoromethyl, wherein q is 0 or 1.

8, the compound of any claim 1-4 of basis, wherein R ¹Be selected from the group of forming by following formula:

With

R wherein ⁸Be selected from amino acid side chain, wherein said amino acid side chain can be naturally occurring or non-natural exists;

Each R wherein ⁹, R ¹⁰And R ¹¹Be selected from hydrogen, alkyl, aryl, heterocyclic radical and heteroaryl;

R wherein ¹²Be selected from the group of forming by heterocyclic radical, heteroaryl, aryl and alkyl;

R wherein ¹³Be selected from (C ₁-C ₃)-alkyl and aryl.

9, compound according to Claim 8, wherein R ¹Be selected from the group of forming by following formula: With

R wherein ⁸Be selected from the group of forming by tryptophane side chain and lysine side-chain;

Each R wherein ¹⁰And R ¹¹Be independently selected from the group of forming by hydrogen and alkyl;

R wherein ¹²Be selected from the group of forming by imidazolyl, N-methylimidazolyl, indyl, quinolyl, benzyloxy benzyl and benzyl piepridine base benzyl;

Wherein X is selected from the group of being made up of fluorine and trifluoromethyl.

10, according to any compound of claim 1-4, wherein J be selected from by hydrogen, amino, azido-and

The group of forming;

R wherein ¹⁷And R ¹⁸Primordial group together, be selected from by ketone acetal,

With The group of forming;

Perhaps wherein if R ¹⁸Be hydrogen, R then ¹⁷It is hydroxyl;

Perhaps wherein J and R ¹⁷Constitute heterocyclic ring together.

11, according to the compound of claim 10, R wherein ²Be selected from the group of forming by following formula:

With

The group of forming.

12, according to the compound of claim 11, R wherein ²Be

13, according to the compound of any claim 1-4, wherein said compound is selected from:

14, according to the compound of claim 13, wherein said compound is selected from:

15, pharmaceutical composition comprises compound and pharmaceutically acceptable carrier according to any claim 1-5.

16, the method for treatment curee infectation of bacteria, comprise with significant quantity on the therapeutics according to the pharmaceutical composition of claim 15 step to its curee's administration of needs.

17, according to the method for claim 16, the group that wherein said curee selects freeman, animal, cell culture and plant to form.

18, according to the method for claim 16, wherein said infectation of bacteria is caused by gram positive bacterium.

19, according to the method for claim 18, wherein said bacterium is the antibiotic resistance bacterium.

20, according to the method for claim 19, wherein said antibiotic resistance bacterium is a tolerance to the microbiotic that is selected from the group of being made up of vancomycin, X-1497, glycopeptide antibiotic, penicillin and daptomycin.

21,, further comprise the step of more than one formulas (I) compound to their curee's co-administered of needs according to the method for claim 16.

22,, further comprise the step of the biocide except that formula (I) compound to its curee's co-administered of needs according to the method for claim 16.

23, method according to claim 22, wherein said biocide is selected from penicillins and relevant medicine, carbon penicillin alkene class, cephalosporins and relevant medicine, aminoglycosides, bacitracin, linear gramicidins, mupirocin, paraxin, thiamphenicol, Sodium Fusidate, lincomycin, clindamycin, Macrolide, Vulkamycin. PA-93, polymyxins, rifomycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramin, antifol, comprise sulfamido, trimethoprim and combination thereof and Pyrimethamine hcl, the synthetic antiseptic-germicide, comprise itrofurans, hexamine mandelate and methenamine hippu, nitro glyoxaline, quinolones, fluoroquinolones, the vazadrine, Tibutol, pyrazinoic acid amide, right-aminosallcylic acid (PAS), seromycin, capromycin, ethionamide, Protionamide, Thioacetazone, Viothenate, everninomicin, glycopeptide, glycylcylcline, ketolides oxazolidone; Imipenum, amikacin, netilmicin, phosphonomycin, gentamicin, ceftriaxone, Ziracin, LY 333328, CL 331002, HMR 3647, Linezolide, Synercid, aztreonam, metronidazole, epiroprim, OCA-983, GV-143253, Sanfetrinem sodium, CS-834, biapenem, A-99058.1, A-165600, A-179796, KA 1 59, Dynemicin A, DX 8739, DU 6681; Cefluprenam, ER 35786, Cefoselis, Sanfetrinemcelexetil, HGP-31, cefpirome, HMR-3647, RU-59863, Mersacidin, KP 736, Rifalazil; Kosan, AM 1732, MEN 10700, Lenapenem, BO 2502A, NE-1530, PR 39, K 130, OPC 20000, OPC 2045, Veneprim, PD 138312, PD 140248, CP 111905, sulopenem, ritipenem acoxyl, RO-65-5788, Cyclothialidine, Sch-40832, SEP-132613, micacocicin A, SB-275833, SR-15402, SUN A0026, TOC 39, carumonam, Cefozopran, cefetamet pivalyl oxygen formyl and T 3811.

24, according to the method for claim 22, wherein said biocide is selected from the group of being made up of imipenum, amikacin, netilmicin, phosphonomycin, gentamicin, ceftriaxone, teicoplanin, Ziracin, LY 333328, CL 331002, HMR 3647, Linezolide, Synercid, aztreonam and metronidazole.

25, according to the method for claim 17, wherein said curee is selected from the human or animal.

26, according to the method for claim 25, wherein said curee is the people.

27, formula (II) compound:

R wherein ¹⁴Be selected from by

With

The group of forming, wherein R ⁵⁶It is optional substituted straight chain C ₈-C ₁₄Alkyl, wherein q ' is 0-3.

28, according to the compound of claim 27, wherein said compound is selected from:

29, formula (I ') compound:

And salt; R wherein ¹⁰⁰, R ¹⁰¹And R ¹⁰²Be selected from:

30, utilize the method for the compound of one of any claim 27-29 of basis according to the compound of one of any claim 1-4.